TY - JOUR
T1 - Analysis of Covid-19 Neutralizing Antibody Levels Post Vaccination using IchromaTMand iFlash Covid-19 Nab
AU - Kahar, Hartono
AU - Prasetyaningrum, Sari Prabandari
AU - Fitriah, Munawaroh
AU - Aryati,
AU - Nugraha, Jusak
N1 - Publisher Copyright:
© 2023 Phcogj.Com.
PY - 2023/1
Y1 - 2023/1
N2 - Background: One of the efforts to control SARS-CoV-2 infection in health workers is vaccination. In this study, the levels of SARS-CoV-2 neutralizing antibody (nAb) in health workers were measured with Ichroma and iFlash. Methods: This study applied an observational analytic design with a prospective cohort and was conducted at Dr. Soetomo Regional Public Hospital, Surabaya, from January to November 2021. The population of this study included a total of 75 health workers after taking the second dose of the SARS-CoV-2 (Sinovac) vaccine. The Covid-19 NAb levels of the population were tested with Ichroma and iFlash on day 0 before vaccination, as well as days 14 and 28, and months 3 and 6 after vaccination. Results: The Friedman test indicated a significant difference in NAb levels according to the iFlash test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p < 0.05). The Wilcoxon test revealed a significant difference in NAb levels on day 14, day 28, month 3, and month 6. The results of the Cochran test showed a significant difference in the positivity of NAb according to the Ichroma test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p < 0.05). McNemar's test demonstrated that the COI at month 3 was not significantly different from that before vaccination; The COI at month 6 was not significantly different from those at days 14 and 28. The results of the Pearson correlation test and Bland-Altman plot indicated a moderate correlation between Ichroma and iFlash (r = 0.592, p = 0.002). Conclusion: Neutralizing antibodies for Covid-19 were formed after day 14 and started to increase on day 28 and started to decrease in months 3 and 6. The levels of NAb for Covid-19 were measured with Ichroma and iFlash in roughly the same pattern and had a moderate positive correlation.
AB - Background: One of the efforts to control SARS-CoV-2 infection in health workers is vaccination. In this study, the levels of SARS-CoV-2 neutralizing antibody (nAb) in health workers were measured with Ichroma and iFlash. Methods: This study applied an observational analytic design with a prospective cohort and was conducted at Dr. Soetomo Regional Public Hospital, Surabaya, from January to November 2021. The population of this study included a total of 75 health workers after taking the second dose of the SARS-CoV-2 (Sinovac) vaccine. The Covid-19 NAb levels of the population were tested with Ichroma and iFlash on day 0 before vaccination, as well as days 14 and 28, and months 3 and 6 after vaccination. Results: The Friedman test indicated a significant difference in NAb levels according to the iFlash test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p < 0.05). The Wilcoxon test revealed a significant difference in NAb levels on day 14, day 28, month 3, and month 6. The results of the Cochran test showed a significant difference in the positivity of NAb according to the Ichroma test on day 14, day 28, month 3, and month 6 compared to those before vaccination (p < 0.05). McNemar's test demonstrated that the COI at month 3 was not significantly different from that before vaccination; The COI at month 6 was not significantly different from those at days 14 and 28. The results of the Pearson correlation test and Bland-Altman plot indicated a moderate correlation between Ichroma and iFlash (r = 0.592, p = 0.002). Conclusion: Neutralizing antibodies for Covid-19 were formed after day 14 and started to increase on day 28 and started to decrease in months 3 and 6. The levels of NAb for Covid-19 were measured with Ichroma and iFlash in roughly the same pattern and had a moderate positive correlation.
KW - Ichroma
KW - Neutralizing Antibody
KW - iFlash
UR - http://www.scopus.com/inward/record.url?scp=85152109218&partnerID=8YFLogxK
U2 - 10.5530/pj.2023.15.25
DO - 10.5530/pj.2023.15.25
M3 - Article
AN - SCOPUS:85152109218
SN - 0975-3575
VL - 15
SP - 171
EP - 174
JO - Pharmacognosy Journal
JF - Pharmacognosy Journal
IS - 1
ER -